Dr Hoenle AG
XETRA:HNL
Intrinsic Value
Dr. Hönle AG engages in the development, manufacture, and sale of light-emitting diode ultraviolet (UV) products. [ Read More ]
The intrinsic value of one HNL stock under the Base Case scenario is 23.45 EUR. Compared to the current market price of 20 EUR, Dr Hoenle AG is Undervalued by 15%.
Valuation Backtest
Dr Hoenle AG
Run backtest to discover the historical profit from buying and selling HNL stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Dr Hoenle AG
Current Assets | 62m |
Cash & Short-Term Investments | 8.6m |
Receivables | 15.8m |
Other Current Assets | 37.7m |
Non-Current Assets | 106m |
Long-Term Investments | 1.4m |
PP&E | 74.1m |
Intangibles | 19.6m |
Other Non-Current Assets | 10.9m |
Current Liabilities | 28.3m |
Accounts Payable | 6.5m |
Other Current Liabilities | 21.8m |
Non-Current Liabilities | 46.4m |
Long-Term Debt | 41.8m |
Other Non-Current Liabilities | 4.7m |
Earnings Waterfall
Dr Hoenle AG
Revenue
|
130.1m
EUR
|
Cost of Revenue
|
-62.5m
EUR
|
Gross Profit
|
67.6m
EUR
|
Operating Expenses
|
-77.7m
EUR
|
Operating Income
|
-10.1m
EUR
|
Other Expenses
|
-1.8m
EUR
|
Net Income
|
-11.9m
EUR
|
Free Cash Flow Analysis
Dr Hoenle AG
What is Free Cash Flow?
HNL Profitability Score
Profitability Due Diligence
Dr Hoenle AG's profitability score is 34/100. The higher the profitability score, the more profitable the company is.
Score
Dr Hoenle AG's profitability score is 34/100. The higher the profitability score, the more profitable the company is.
HNL Solvency Score
Solvency Due Diligence
Dr Hoenle AG's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Score
Dr Hoenle AG's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
HNL Price Targets Summary
Dr Hoenle AG
According to Wall Street analysts, the average 1-year price target for HNL is 26.72 EUR with a low forecast of 23.63 EUR and a high forecast of 30.45 EUR.
Shareholder Return
HNL Price
Dr Hoenle AG
Average Annual Return | -17.52% |
Standard Deviation of Annual Returns | 34.47% |
Max Drawdown | -80% |
Market Capitalization | 121.8m EUR |
Shares Outstanding | 6 061 854 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Dr. Hönle AG engages in the development, manufacture, and sale of light-emitting diode ultraviolet (UV) products. The company is headquartered in Graefelfing, Bayern and currently employs 657 full-time employees. The company went IPO on 2008-02-25. The firm develops, manufactures and supplies ultraviolet (UV) equipment. The firm operates three business segments: Equipment and Systems, Adhesives, and Glass and Lamps. The Equipment and Systems segment encompasses the development, production and sale of UV equipment and systems used for drying inks and coatings, for curing adhesives and plastics, disinfecting surfaces and for sunlight simulation. The Adhesives segment comprises the development, production and sale of UV industrial adhesives for the use in the automotive, electronics, medical technology and optics industries, among others. The Glass and Lamps segment includes the development, production and sale of tubing and semi-finished goods made from quartz glass as well as the manufacture of UV medium-pressure and low-pressure lamps. The firm is globally active, with over 69 locations in 27 countries.
Contact
IPO
Employees
Officers
The intrinsic value of one HNL stock under the Base Case scenario is 23.45 EUR.
Compared to the current market price of 20 EUR, Dr Hoenle AG is Undervalued by 15%.